BIOMAT Database Logo BIOMAT Database Logo

The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. 1993

A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Institute of Neurology C. Mondino, Pavia, Italy.

The kinetics of oxcarbazepine (OXC) and its active metabolite 10-hydroxy-carbazepine (10-OH-CZ) after a single oral OXC dose (600 mg) were compared in healthy control subjects and in epileptic patients treated with phenobarbitone or sodium valproate (n = 8 in each group). In all groups, serum 10-OH-CZ concentrations were much higher than those of the parent drug. In patients on valproate, the kinetics of OXC and 10-OH-CZ did not differ significantly from those observed in controls. In patients on phenobarbitone, AUC values of both OXC and 10-OH-CZ were lower than in controls (2.9 +/- 0.4 vs 5.1 +/- 0.7 microg ml(-1) h and 89 +/- 7 vs 119 +/- 10 microg ml(-1) h respectively, means +/- s.e. mean, P < 0.05), whereas 10-OH-CZ half-lives were only marginally shorter (17 +/- 1 h vs 20 +/- 2 h, NS). These data indicate that the biotransformation of OXC and 10-OH-CZ may be accelerated by concomitant treatment with phenobarbitone but that the magnitude of this effect is unlikely to be of great clinical significance.

UI MeSH Term Description Entries
D008297 Male Males
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D002220 Carbamazepine A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties. Amizepine,Carbamazepine Acetate,Carbamazepine Anhydrous,Carbamazepine Dihydrate,Carbamazepine Hydrochloride,Carbamazepine L-Tartrate (4:1),Carbamazepine Phosphate,Carbamazepine Sulfate (2:1),Carbazepin,Epitol,Finlepsin,Neurotol,Tegretol
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078330 Oxcarbazepine A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4. 10,11-Dihydro-10-oxo-5H-dibenz(b,f)azepine-5-carboxamide,GP 47680,Timox,Trileptal
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother.
January 1988, European journal of clinical pharmacology,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Population pharmacokinetics of oxcarbazepine and its metabolite 10-hydroxycarbazepine in healthy subjects.
November 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Fluctuations of 10-hydroxy-carbazepine during the day in epileptic patients.
June 1996, Acta neurologica Scandinavica,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite.
January 1989, European journal of clinical pharmacology,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Pharmacokinetics of 10-OH-carbazepine, the main metabolite of the antiepileptic oxcarbazepine, from serum and saliva concentrations.
September 1983, Acta neurologica Scandinavica,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Gas chromatographic/mass spectrometric assays for oxcarbazepine and its main metabolites, 10-hydroxy-carbazepine and carbazepine-10,11-trans-diol.
December 1986, Biomedical & environmental mass spectrometry,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers.
February 2016, European journal of clinical pharmacology,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
March 2015, International journal of clinical pharmacology and therapeutics,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects.
July 2003, Acta pharmacologica Sinica,
A Tartara, and C A Galimberti, and R Manni, and R Morini, and G Limido, and G Gatti, and A Bartoli, and G Strada, and E Perucca
Pharmacokinetics of Losartan and its Active Metabolite EXP3174 in Healthy Iranian Subjects.
January 2004, Clinical drug investigation,
Copied contents to your clipboard!